Archive August 19, 2022 Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Archive August 10, 2022 Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
Archive August 4, 2022 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
Archive July 28, 2022 Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022
Archive July 15, 2022 Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Archive June 16, 2022 Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer
Archive May 2, 2022 Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
Archive April 29, 2022 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
